SCHEMBL30748747

SCHEMBL30748747

OCc1ncc(C2CCOCC2)c(Nc2ccc(N3CCOCC3)nc2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 2/20 0.51
FLT3 P36888 2/20 0.46
BTK Q06187 3/20 0.44
IGF1R P08069 1/20 0.43
KCNH2 Q12809 1/20 0.43
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
PTK6 Q13882 1/20 0.40
CDK2 P24941 1/20 0.40
MARK3 P27448 1/20 0.40
IKBKE Q14164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749029 0.85 FLT3 (0.47) TBK1FLT3BTKIGF1RKCNH2
SCHEMBL30749026 0.77 GAA (0.40) TBK1FLT3BTKKCNH2MAPT
SCHEMBL30748815 0.76 SORD (0.47) IGF1RMAPTSMN1; SMN2LMNACYP1A2
SCHEMBL3383970 0.72 TBK1 (0.72) TBK1IGF1RCDK2MARK3IKBKE
SCHEMBL3383966 0.72 TBK1 (0.71) TBK1BTKIGF1RKCNH2CDK2
SCHEMBL3388094 0.71 TBK1 (0.75) TBK1IGF1RCDK2MARK3IKBKE
SCHEMBL3388099 0.71 TBK1 (0.73) TBK1IGF1RCDK2MARK3IKBKE
SCHEMBL31691218 0.71 FLT3 (0.42) TBK1FLT3BTKIGF1RKCNH2
Hydrochloric Acid SCHEMBL3389146 0.71 TBK1 (0.72) TBK1IGF1RCDK2MARK3IKBKE
SCHEMBL13653574 0.70 TBK1 (0.69) TBK1IGF1RCDK2MARK3IKBKE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT TBK1 3998/4885FLT3 2266/4885BTK 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.